| Nov 5 |
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
|
| Nov 5 |
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
|
| Nov 4 |
Cellectis GAAP EPS of -$0.23 misses by $0.02, revenue of $18.05M beats by $8.95M
|
| Nov 4 |
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
|
| Oct 23 |
Cellectis Presents New Gene-Editing Breakthroughs
|
| Sep 17 |
Cibus announces proposed public offering of Class A common stock
|
| Sep 3 |
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
|
| Aug 26 |
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
|
| Aug 7 |
Cellectis names Adrian Kilcoyne as chief medical officer
|
| Aug 7 |
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
|
